Mobile

A Phase IV multicentre, randomised, double-blind, placebo controlled, trial to evaluate the safety and efficacy of Raptiva ® in the treatment of subjects with moderate to severe plaque psoriasis invol...

Mise à jour : Il y a 5 ans
Référence : EUCTR2007-004227-37

A Phase IV multicentre, randomised, double-blind, placebo controlled, trial to evaluate the safety and efficacy of Raptiva ® in the treatment of subjects with moderate to severe plaque psoriasis involving hands and/or feet, with or without pustules

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and efficacy of Raptiva ® against placebo to control chronic moderate to severe plaque-type psoriasis involving hands and/or feet scoring PGA (PGA - H&F) ≥3 in subjects not suitable for other systemic therapies including cyclosporine, methotrexate, and PUVA.

Critère d'inclusion

  • Subject with chronic (disease history of at least 6 months from diagnosis) moderate to severe plaque psoriasis involving the hands and/or feet (PGA – H&F ratings of 3 or 4) at screening, who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate and PUVA

Liens